Cederquist Gustav Y, Tringale Kathryn, Yahalom Joachim, Imber Brandon S
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York NY.
Department of Radiation Medicine and Applied Sciences, University of California, San Diego, CA.
Semin Radiat Oncol. 2025 Jan;35(1):126-137. doi: 10.1016/j.semradonc.2024.11.001.
The contemporary landscape of systemic therapy options for hematologic malignancies involving the central nervous system (CNS-HM) is rapidly evolving; a key question is how radiotherapy (RT) can be optimally integrated to improve patient outcomes. Historically, use of RT to treat CNS-HM was defined by broad fields and high doses. While effective, this approach raised concerns of potential neurotoxicity which significantly decreased RT utilization. RT was replaced by high-dose, CNS-penetrant, systemic therapies that offered durable control with lower perceived neurotoxic risk. But, as the therapeutic toolbox for CNS-HM expands, so too does the complexity and diversity of potential clinical scenarios where RT should be considered. In this review, we describe both well-established and emerging opportunities for RT integration, emphasizing how dose selection and field design could balance neurotoxicity risk and disease control. We propose an anatomical framework that captures the diverse utilization of RT for CNS-HM and serves as a practical guide for RT volume and dose design.
涉及中枢神经系统的血液系统恶性肿瘤(CNS-HM)的当代全身治疗选择格局正在迅速演变;一个关键问题是如何最佳地整合放射治疗(RT)以改善患者预后。从历史上看,使用RT治疗CNS-HM的方式是采用大野和高剂量。虽然这种方法有效,但引发了对潜在神经毒性的担忧,这显著降低了RT的使用。RT被高剂量、可穿透中枢神经系统的全身治疗所取代,这些治疗提供了持久的控制,且被认为神经毒性风险较低。但是,随着CNS-HM治疗工具箱的扩展,应考虑RT的潜在临床情况的复杂性和多样性也在增加。在本综述中,我们描述了RT整合的既定和新出现的机会,强调剂量选择和野设计如何平衡神经毒性风险和疾病控制。我们提出了一个解剖学框架,该框架涵盖了RT在CNS-HM中的不同应用,并作为RT体积和剂量设计的实用指南。